Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
Rakesh Awasthi, Harald J. Maier, Jie Zhang, Stephen Lim
Abstract
The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.
Topics & Concepts
BlinatumomabMedicineImmunotherapyOncologyLymphomaCytokine release syndromeFollicular lymphomaInternal medicineRefractory (planetary science)Clinical trialChimeric antigen receptorImmunologyIntensive care medicineLeukemiaLymphoblastic LeukemiaCancerBiologyAstrobiologyCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsCRISPR and Genetic Engineering